153 related articles for article (PubMed ID: 23988183)
1. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
Iversen AB; Busk M; Horsman MR
Acta Oncol; 2013 Oct; 52(7):1320-6. PubMed ID: 23988183
[TBL] [Abstract][Full Text] [Related]
2. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
Hokland SL; Horsman MR
Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
[TBL] [Abstract][Full Text] [Related]
3. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Horsman MR
Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation.
Horsman MR
Int J Hyperthermia; 2015; 31(5):453-9. PubMed ID: 25915829
[TBL] [Abstract][Full Text] [Related]
5. Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
Horsman MR; Wittenborn TR; Nielsen PS; Elming PB
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640548
[TBL] [Abstract][Full Text] [Related]
6. Combination of vascular targeting agents with thermal or radiation therapy.
Horsman MR; Murata R
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1518-23. PubMed ID: 12459380
[TBL] [Abstract][Full Text] [Related]
7. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy.
Wittenborn TR; Horsman MR
Acta Oncol; 2015; 54(9):1385-92. PubMed ID: 26329662
[TBL] [Abstract][Full Text] [Related]
9. Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.
Bertelsen LB; Bohn AB; Shen YY; Falborg L; Stødkilde-Jørgensen H; Horsman MR
BMC Cancer; 2014 Dec; 14():903. PubMed ID: 25466422
[TBL] [Abstract][Full Text] [Related]
10. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
[TBL] [Abstract][Full Text] [Related]
11. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036
[TBL] [Abstract][Full Text] [Related]
12. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Siemann DW; Overgaard J; Horsman MR
Radiat Res; 2001 Nov; 156(5 Pt 1):503-9. PubMed ID: 11604063
[TBL] [Abstract][Full Text] [Related]
13. Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response.
Horsman MR; Nielsen T; Østergaard L; Overgaard J
Acta Oncol; 2006; 45(7):876-80. PubMed ID: 16982553
[TBL] [Abstract][Full Text] [Related]
14. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
[TBL] [Abstract][Full Text] [Related]
15. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
Rice L; Pampo C; Lepler S; Rojiani AM; Siemann DW
Microvasc Res; 2011 Jan; 81(1):44-51. PubMed ID: 20974154
[TBL] [Abstract][Full Text] [Related]
16. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
Murata R; Tsujitani M; Horsman MR
Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
[TBL] [Abstract][Full Text] [Related]
17. Vascular disrupting agents.
Lippert JW
Bioorg Med Chem; 2007 Jan; 15(2):605-15. PubMed ID: 17070061
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Overgaard J; Horsman MR
Int J Hyperthermia; 2001; 17(6):508-19. PubMed ID: 11719967
[TBL] [Abstract][Full Text] [Related]
19. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.
Horsman MR; Murata R
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1047-55. PubMed ID: 14575836
[TBL] [Abstract][Full Text] [Related]
20. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
Siim BG; Laux WT; Rutland MD; Palmer BN; Wilson WR
Cancer Res; 2000 Aug; 60(16):4582-8. PubMed ID: 10969810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
